Researchers explore the antidepressant effects of ketamine

Feb 21, 2008

Drug treatments for depression can take many weeks for the beneficial effects to emerge. The excruciating and disabling nature of depression highlights the urgency of developing treatments that act more rapidly. Ketamine, a drug used in general medicine as an anesthetic, has recently been shown to produce improvements in depressed patients within hours of administration. A new study being published in the February 15th issue of Biological Psychiatry provides some new insight into the mechanisms by which ketamine exerts its effects.

Ketamine is classified as an N-methyl d-aspartate (NMDA) glutamate receptor antagonist. Maeng and colleagues now provide new evidence that these antidepressant effects of NMDA receptor antagonists are mediated by their ability to increase the stimulation of á-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors.

In other words, their findings indicate that the antidepressant-like effects of drugs like ketamine are dependent on AMPA receptor stimulation. This suggests that drugs that enhance AMPA receptor function might have rapid antidepressant properties.

Dr. Husseini Manji, corresponding author on this paper and a Deputy Editor of Biological Psychiatry, explains that “by aiming new medications at more direct molecular targets, such as NMDA or AMPA, we may be able to bypass some of the steps through which current antidepressants indirectly exert their effects — a roundabout route that accounts for the long time it takes for patients to begin feeling better with the conventional medications.” He adds, “Today’s antidepressant medications eventually end up doing the same thing, but they go about it the long way around, with a lot of biochemical steps that take time. Now we’ve shown what the key targets are and that we can get at them rapidly.”

This study is especially important because even though this important antidepressant effect has been found in ketamine, its use also has significant drawbacks. According to John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, “the only NMDA receptor antagonist found to be effective so far, ketamine, produces transient changes in perception and impairments in cognition.”

It is also in the same class of drugs as PCP (phencyclidine) and can cause hallucinations, among other side effects. Dr. Krystal notes that “it is possible that drugs that directly enhance the activity of AMPA glutamate receptors, the AMPAkines, would have antidepressant effects similar to ketamine, without the unwanted side effects.” Exploring the antidepressant effects of the AMPAkines will now be an important target for researchers.

Source: Elsevier

Explore further: Predicting antibiotic resistance

add to favorites email to friend print save as pdf

Related Stories

Uncovering the neurobiological basis of general anesthesia

Dec 30, 2010

The use of general anesthesia is a routine part of surgical operations at hospitals and medical facilities around the world, but the precise biological mechanisms that underlie anesthetic drugs' effects on the brain and the ...

Researchers describe secrets of 'magic' antidepressant

Aug 19, 2010

Yale researchers have discovered how a novel anti-depressant can take effect in hours, rather than the weeks or months usually required for most drugs currently on the market. The findings, described in the ...

A new generation of rapid-acting antidepressants?

Mar 01, 2010

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to ...

Ketamine reduces suicidality in depressed patients

Sep 10, 2009

Drug treatment options for depression can take weeks for the beneficial effects to emerge, which is clearly inadequate for those at immediate risk of suicide. However, intravenous (IV) ketamine, a drug previously used as ...

Migraine prevention by targeting glutamate receptors?

Apr 29, 2009

When migraine strikes, because of severe pain, often accompanied by nausea and sensitivity to light and sound, sufferers are effectively disabled for up to 72 hours. Since they are forced to stop what they are doing until ...

Recommended for you

Stem cells faulty in Duchenne muscular dystrophy

9 hours ago

Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the Stanford University School of Medicine have ...

Here's how the prion protein protects us

13 hours ago

The cellular prion protein (PrPC) has the ability to protect the brain's neurons. Although scientists have known about this protective physiological function for some time, they were lacking detailed knowledge ...

Regulation of maternal miRNAs in early embryos revealed

14 hours ago

The Center for RNA Research at the Institute for Basic Science (IBS) has succeeded in revealing, for the first time, the mechanism of how miRNAs, which control gene expression, are regulated in the early embryonic stage.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.